Cardene (nicardipine) / Chiesi - LARVOL DELTA

iVASTt: The Intra-arterial Vasospasm Trial (clinicaltrials.gov) - P4 | N=92 | Terminated | Sponsor: Peng Roc Chen, MD | N=330 ➔ 92 | Trial completion date: Dec 2024 ➔ Aug 2024 | Recruiting ➔ Terminated; Slow enrollment

Enrollment change • Trial completion date • Trial termination

Hypotensive Anesthesia for Orthognathic Surgery (clinicaltrials.gov) - P4 | N=90 | Recruiting | Sponsor: Boston Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Anesthesia

Hypotensive Anesthesia for Orthognathic Surgery (clinicaltrials.gov) - P4 | N=90 | Not yet recruiting | Sponsor: Boston Medical Center | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Adverse events • Trial completion date • Trial primary completion date • Anesthesia

Hypotensive Anesthesia for Orthognathic Surgery (clinicaltrials.gov) - P4 | N=90 | Not yet recruiting | Sponsor: Boston Medical Center | Trial completion date: Mar 2025 ➔ Jul 2025 | Trial primary completion date: Mar 2025 ➔ Jul 2025

Adverse events • Surgery • Trial completion date • Trial primary completion date • Anesthesia

CARDIAC SEIZURE: A NEUROCARDIAC PHENOMENON (CHEST 2024) - "In conclusion, cardiac seizure is a neurocardiac phenomenon that can mimic true neurological seizure disorders. A high index of suspicion is required for accurate differentiation and diagnosis. Clinicians should consider cardiac etiologies in patients presenting with a syncope and seizure-like activity, especially in the presence of cardiac risk factors or abnormalities."

Alzheimer's Disease • Amyloidosis • Cardiovascular • CNS Disorders • Dementia • Epilepsy • Hypertension • Mood Disorders

EISENMENGER SYNDROME: INSIGHTS FROM A FATAL CASE (CHEST 2024) - "She was subsequently transferred to our facility for ECMO evaluation where she was treated with inhaled nitric oxide, milrinone drip, and sildenafil...Intravenous epoprostenol was unavailable at our facility, therefore Sildenafil was used... With this report, we aim to enhance the understanding of this complex pathological presentation. It underscores the importance of a multi-disciplinary team, early referral for transplantation and a proactive stance to preserve hemodynamics, preempt complications, and promptly initiate targeted therapies. Furthermore, it emphasizes the need for evidence-based, consensus-driven treatment guidelines for patients with Eisenmenger syndrome which are currently lacking (3)"

Clinical • Cardiovascular • Cough • Heart Failure • Hematological Disorders • Hypotension • Polycythemia Vera • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Hypotensive Anesthesia for Orthognathic Surgery (clinicaltrials.gov) - P4 | N=90 | Not yet recruiting | Sponsor: Boston Medical Center | Initiation date: Aug 2024 ➔ Nov 2024

Adverse events • Surgery • Trial initiation date • Anesthesia

Post-partum Inpatient Rehabilitation to Facilitate Recovery After HELLP Syndrome Complicated by Severe Stroke: A Case Report (AAPMR 2023) - "Although the incidence of stroke during pregnancy is relatively low, preeclampsia remains a significant risk factor for peripartum stroke. This patient did not receive adequate prenatal care, or follow-up during pregnancy, thus placing her at risk. This case describes the uncommon situation of preeclampsia with HELLP syndrome presenting initially as a severe stroke, highlighting the importance of immediate IPR to maximize functional recovery."

Clinical • Cardiovascular • Cerebral Hemorrhage • Gastrointestinal Disorder • Gynecology • Hematological Disorders • Hypertension

Cost Consequences of Using Clevidipine in Cardiac Surgery from the Perspective of a US Hospital (ISPOR-EU 2023) - " A decision analytic model was developed to simulate the costs and consequences associated with the use of clevidipine, sodium nitroprusside, and nicardipine in patients undergoing cardiac surgery experiencing hypertension. The increased use of clevidipine in cardiac surgery patients results in improved outcomes and cost savings over the 3 years, especially due to a reduction in total hospital stay."

Clinical • Surgery • Cardiovascular • Hypertension

Cost Consequences of Using Clevidipine in Neurological Emergencies from the Perspective of a US Hospital (ISPOR-EU 2023) - " A decision analytic model was developed to simulate the costs and consequences associated with the use of clevidipine, labetalol, and nicardipine in patients experiencing a neurological emergency with acute hypertension. The increased use of clevidipine for patients with a neurological emergency with acute hypertension results in more patients reaching BP target in less time with a decrease in the cost over the 3 years."

Clinical • Cardiovascular • Hypertension

Cost Consequences of Using Clevidipine in Acute Hypertension from the Perspective of a US Hospital (ISPOR-EU 2023) - " A decision analytic model was developed to simulate the costs and consequences associated with the use of clevidipine, labetalol, and nicardipine in patients with severe aHTN in the emergency room or critical care setting. The increased use of clevidipine in patients with aHTN results in more patients reaching BP target in less time with a decrease in the cost over the 3 years."

Clinical • Cardiovascular • Critical care • Hypertension

"https://t.co/L3N62r2Rv4 Dr Higinia Cardenes is one of the pioneers in SBRT for HCC. @ldawsonmd is also a pioneer, of course." (@SimonLo21054188)

Decreased Timing to Vasospasm Prevention Medication Improves Outcomes Among Patients with Aneurysmal Subarachnoid Hemorrhage on Prehospital CCBs, ARBs, or ACE-inhibitors (AAN 2023) - "Objective It remains unclear how the timing of in-hospital calcium channel blockers (CCBs; Nimodipine or Cardene) initiation effects the risk for vasospasm after aneurysmal subarachnoid hemorrhage (aSAH)...Conclusions While larger studies are needed, this study showed that those on prehospital CCBs, ACE-inhibitors, or ARBs, receipt of in-hospital CCBs ≤ 1 hour of arrival significantly reduced the vasospasm rate, HLOS, and death rate. Reducing disruption times in prehospital antihypertensive treatment through in-hospital CCB receipt ≤ 1 hour of arrival, may prevent worsened outcomes."

Clinical • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage

BEST-II: Blood Pressure After Endovascular Stroke Therapy-II (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: University of Cincinnati | Active, not recruiting ➔ Completed | Trial completion date: Aug 2022 ➔ Dec 2022

Trial completion • Trial completion date • Cardiovascular

BEST-II: Blood Pressure After Endovascular Stroke Therapy-II (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: University of Cincinnati | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2023 ➔ May 2022 | Trial primary completion date: Mar 2023 ➔ May 2022

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular

"thrombotic rca with no reflow last week-penumbra-distal delivery of cardene only-thankfully timi 3 flow" (@michigan1978)

iVASTt: The Intra-arterial Vasospasm Trial (clinicaltrials.gov) - P4; N=330; Recruiting; Sponsor: The University of Texas Health Science Center, Houston; Trial completion date: Dec 2021 ➔ Dec 2024; Trial primary completion date: Aug 2021 ➔ Jun 2024

Clinical • Trial completion date • Trial primary completion date